- Home
- VLO vs ONC Comparison
VLO vs ONC Comparison
Compare VLO & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLO
- ONC
- Stock Information
- Founded
- VLO 1980
- ONC 2010
- Country
- VLO United States
- ONC Switzerland
- Employees
- VLO N/A
- ONC N/A
- Industry
- VLO Integrated oil Companies
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- VLO Energy
- ONC Health Care
- Exchange
- VLO Nasdaq
- ONC Nasdaq
- Market Cap
- VLO 45.3B
- ONC 37.3B
- IPO Year
- VLO N/A
- ONC N/A
- Fundamental
- Price
- VLO $162.00
- ONC $334.59
- Analyst Decision
- VLO Buy
- ONC Strong Buy
- Analyst Count
- VLO 15
- ONC 10
- Target Price
- VLO $168.07
- ONC $344.70
- AVG Volume (30 Days)
- VLO 3.0M
- ONC 218.6K
- Earning Date
- VLO 10-23-2025
- ONC 11-11-2025
- Dividend Yield
- VLO 2.79%
- ONC N/A
- EPS Growth
- VLO N/A
- ONC N/A
- EPS
- VLO 2.41
- ONC N/A
- Revenue
- VLO $117,549,000,000.00
- ONC $4,562,002,000.00
- Revenue This Year
- VLO N/A
- ONC $881.07
- Revenue Next Year
- VLO N/A
- ONC N/A
- P/E Ratio
- VLO $67.16
- ONC N/A
- Revenue Growth
- VLO N/A
- ONC 47.33
- 52 Week Low
- VLO $99.00
- ONC $170.99
- 52 Week High
- VLO $178.43
- ONC $355.30
- Technical
- Relative Strength Index (RSI)
- VLO 51.97
- ONC 52.74
- Support Level
- VLO $158.87
- ONC $334.53
- Resistance Level
- VLO $168.50
- ONC $353.00
- Average True Range (ATR)
- VLO 4.58
- ONC 7.28
- MACD
- VLO -1.80
- ONC -0.50
- Stochastic Oscillator
- VLO 14.57
- ONC 41.63
About VLO Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 15 refineries, with a total throughput capacity of 3.2 million barrels a day in the US, Canada, and the United Kingdom. Valero also owns 12 ethanol plants with capacity of 1.6 billion gallons a year and holds a 50% stake in Diamond Green Diesel, which can produce 1.2 billion gallons per year of renewable diesel.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.